Celltrion: 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인)
AI reading
★★★ Bullish · Material event
Zymfentra US Phase 3 clinical trial approval (rheumatoid arthritis)
Key figures: 미국 FDA 임상 3상 승인
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 09.23 ★★ Large Shareholding Report (General)
- 09.21 ★★★ Darzalex biosimilar EU Phase 3 clinical trial approval
- 09.16 ★★ Cancellation of treasury shares for stock price stabilization and shareholder value enhancement
- 09.07 ★★★ Keytruda biosimilar US Phase 3 clinical trial amendment approval
- 09.07 ★★★ Darzalex biosimilar Korea Phase 3 clinical trial amendment approval
- 08.31 ★★★★ 주가 안정 및 주주가치 제고를 위한 자기주식 취득 및 전량 소각 계획
For information only. Not investment advice.